Wednesday, October 18, 2017| Aerie Pharmaceuticals, cellular or cell-based therapy, FDA Approval/Clearance, Gene Therapy, Glaucoma, inherited retinal diseases (IRDs), Spark Therapeutics, Topcon Medical Systems

EyewireTV — Aerie and Spark Receive Positive FDA Committee Votes; New PASCAL Laser Cleared

In this week’s EyewireTV, Aerie Pharmaceuticals receives a favorable vote from the FDA’s Dermatologic and Ophthalmic Drugs advisory committee for glaucoma treatment candidate Rhopressa (netarsudil ophthalmic solution 0.02%); and Spark Therapeutics receives a unanimous recommendation from the FDA's Cellular, Tissue, and Gene Therapies advisory committee for its gene therapy Luxturna (voretigene neparvovec) for use in patients with vision loss due to confirmed biallelic RPE65-mediated inherited retinal disease. Also, Topcon Medical Systems announces that its PASCAL Synthesis TwinStar laser has received FDA 510(k) clearance.

Watch Video

Wednesday, October 11, 2017| Alcon, Alcon, Carl Zeiss Meditec, Clareon AutonoMe, Intraocular lens, IOL, IOLs, Johnson & Johnson Vision Care, OPMI Lumera

EyewireTV — Breaking News Live from the ESCRS Meeting in Lisbon

In this week’s EyewireTV, Alcon introduces the Clareon hydrophobic acrylic IOL and AutonoMe preloaded automated IOL delivery system; and Johnson & Johnson Vision announces the launch of its iDesign 2.0 refractive studio system. Also, Carl Zeiss Meditec releases the AT LARA extended-depth-of-focus IOL and the OPMI LUMERA 700 microscope.

Watch Video

Thursday, September 28, 2017

EyewireTV — New Ophthalmic Company; Alcon On-Demand Education

In this week’s EyewireTV, new ophthalmic company Eyevance Pharmaceuticals enters into an exclusive licensing agreement with Nicox for allergic conjunctivitis drug Zerviate (cetirizine ophthalmic solution); and independent custom lens manufacturer Art Optical Contact Lens receives FDA 510(k) clearance for the Ampleye scleral lens for the therapeutic management of ocular surface disease from dry eye. Also, Alcon develops a new on-demand educational broadcast for its Contoura Vision platform.

Watch Video

Wednesday, September 20, 2017| Johnson & Johnson Vision Care

EyewireTV - J&J Acquires Sightbox; Phase 3 GA Drug Candidate Fails

In this week’s EyewireTV, Johnson & Johnson Vision acquires Sightbox, an online membership-based subscription service for contact lens wearers; and Genentech’s lampalizumab, a drug candidate being evaluated for the treatment of geographic atrophy due to AMD, fails a phase 3 trial. Also, Carl Zeiss Meditec announces the US launch of its next-generation, ultra-widefield fundus imaging system, the CLARUS 500.

Watch Video

Wednesday, September 13, 2017

EyewireTV — Students Provide Reaction from ME Live Meeting in Nashville

In this week’s EyewireTV, residents and trainees provide their reaction to being invited to MillennialEYE Live in Nashville and discuss the pearls they have taken away from the meeting.

Watch Video

Wednesday, September 06, 2017| Acquisitions, Mergers, Alcon, Alcon, CyPass Micro-Stent, Johnson & Johnson Vision Care, Medicare, Novartis, TearScience

EyewireTV - J&J Completes TearScience acquisition; New Novartis CEO

In this week’s EyewireTV, Johnson & Johnson Vision completes its acquisition of privately held TearScience; and Novartis CEO Joseph Jimenez announces he is stepping down from his role in January and will be replaced by Vasant Narasimhan, the company's current global head of drug development and chief medical officer. Also, Alcon announces that the Unique Procedure Code for the CyPass Micro-Stent has become effective, paving the way for Medicare reimbursement.

Watch Video
Load More